OM
Outset Medical, Inc.3.9200
-0.0500-1.26%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Tablo upgrades, pipeline growth detailed
Q&A fleshed out next-gen Tablo details, confirming upgrade access for existing base while touting cybersecurity compliance as a patient-safety tailwind drawing interest across all hospital sizes—potentially accelerating adoption. Management confirmed sales force stability post-leadership exit, with ongoing search and hands-on oversight; pipeline grew at last year's pace, diversified by new/expansion customers and sizes, including critical access hospitals filling rural gaps. Sales cycles span 3-6 months for small deals but stretch 9-12+ for enterprises. No capital budget shifts noted. Pipeline grew, just like last year. Bullish on Tablo launch, investors will track conversion and cybersecurity pull-through.
Key Stats
Market Cap
71.16MP/E (TTM)
-Basic EPS (TTM)
-11.56Dividend Yield
0%Recent Filings
10-K
FY2025 results
Outset Medical narrowed FY2025 net loss to $81.7M from $128.0M in FY2024, with revenue up 5% to $119.5M driven by 6% service growth from installed base expansion, while product revenue rose 5% on higher consumables and console pricing. Q4 showed sequential margin gains, but elongated enterprise sales cycles from macro pressures capped acceleration; gross margin leaped to 39.1% via manufacturing efficiencies at Mexico facility and service leverage. Debt refinanced to $101M term loan at lower rates, bolstering $173M liquidity. No 2026 guidance disclosed. Ongoing FDA scrutiny risks quarterly momentum.
8-K
Q4 results beat margins
Outset Medical posted Q4 revenue of $28.9M, down 2% yet lifting full-year 2025 to $119.5M, up 5% from 2024. Gross margins soared to 42.4% from 36.5%, while opEx dropped 8% to $29.9M, slashing net loss to $19.5M. Cash hit $173M. Guidance eyes $125M-$130M revenue in 2026. FDA-cleared next-gen Tablo launches Q2.
8-K
FDA clears next-gen Tablo
Outset Medical secured FDA 510(k) clearance for its next-generation Tablo hemodialysis platform on January 27, 2026, making it the first dialysis system to meet the agency's toughest cybersecurity standards from June 2025. Hardware, OS, and software upgrades boost reliability and durability for acute settings. Shipments start Q2 2026. Existing users qualify for upgrades.
8-K
Q4 revenue $28.9M; board change
Outset Medical reported preliminary unaudited 2025 revenue of $119.5 million, up 5% from $113.7 million in 2024, with Q4 at $28.9 million and year-end cash at $173 million. Director Andrea Saia resigned effective January 9, 2026; medtech veteran Karen Prange joined the board and Compensation Committee that day, bringing sales expertise from Boston Scientific and Henry Schein. Cash burn slashed below $50 million.
8-K
Q3 revenue up 3%, guide cut
IPO
Employees
Sector
Industry
DXCM
DexCom, Inc.
66.37+0.64
MODD
Modular Medical, Inc.
0.34-0.03
NEPH
Nephros, Inc.
4.85-0.01
NUWE
Nuwellis, Inc.
2.21+0.03
ODYY
Odyssey Health Inc.
0.03+0.00
OMI
Owens & Minor, Inc.
3.10+0.09
OSSFF
EMBLA MEDICAL
5.33+0.00
PODD
Insulet Corporation
288.73-2.78
TMDX
TransMedics Group, Inc.
125.04+1.89
UTMD
Utah Medical Products, Inc.
58.43+0.94